GLUCAGON-LIKE PEPTIDE-1: FROM PHYSIOLOGY TO EFFECTIVE MANAGEMENT OF TYPE 2 DIABETES MELLITUS


Cite item

Full Text

Abstract

In recent years, scientific developments have allowed to thoroughly examine the role of incretin hormones in the regulation of carbohydrate metabolism in the human body and their effect on β-cells, as well as create a new area of pharmacotherapy for type 2 diabetes mellitus. An analysis of the results of several direct comparative studies of different incretin drugs is presented. Today, liraglutide (Victoza) shows high clinical efficacy and safety in comparison with other available incretin preparations.

About the authors

M B Antsiferov

M B Antsiferov

References

  1. Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med. 2009;121(3 Suppl. 1):7-12.
  2. Nathan DM, et al. American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a con-sensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
  3. Rodbard HW, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
  4. Maedler K, et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-6.
  5. Takahashi A, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract 2007;77:343-50.
  6. Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
  7. Riedel AA, et al. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care 2007;13:457-63.
  8. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Am J Med 2009;122(6A, Suppl.):11-24.
  9. U.K. Prospective Diabetes Study Group: Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-58.
  10. Butler AE, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.
  11. Vilsbøll T, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111-19.
  12. Knudsen LB, et al. Potent derivatives of glucagon-like peptide-1with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43(9):1664-69.
  13. Steensgaard DB, et al. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide [abstract]. Diabetes 2008;57(Suppl. 1):552.
  14. Farilla L, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143(11):4397-408.
  15. Buteau J, et al. Glucagon-like peptide-1 induces pancreatic betta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52(1):124-32.
  16. Elbrønd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-404.
  17. Garber A. Incretin effects on beta-cell function, replication and mass: the human perspective. Diabetes Care 2011;34(Suppl. 2):258-63.
  18. Pratley RE, et al.; 1860-LIRA-DPP-4 Study Group: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
  19. Davies M, et al. One-Year Liraglutide Treatment Reduces A1C to a Greater Extent than Sitagliptin, both in Combination with Metformin, Independent of Baseline A1C LevelsDiabetes 2011;60(Suppl. 1):Abstract 2314.
  20. Pratley RE, et al. Diabetes 2011;60(Suppl. 1):Abstract 1119.
  21. Pratley RE, et al. One-Year Liraglutide Treatment Offers Greater Weight Reduction and More Improved Glycemic Control Compared with Sitagliptin, Both in Combination with Metformin. Diabetes 2011;60(Suppl. 1):abstract 2313.
  22. Irie S, et al. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther 2008;46(6):273-79.
  23. Buse JB, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
  24. Buse JB, et al. Frequency and magnitude of antibody forma¬tion are lower with liraglutide than exenatide: LEAD-6 Results (Abstract 676). Presented at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Fla., 2010.
  25. Bayley T, et al. Comparison of Incretin-Based Therapies: Liraglutide Offers Greater Improvements in A1C than Sitagliptin or Exenatide Across Baseline A1C Categories. Diabetes 2011;60(Suppl. 1):Abstract 2252.
  26. Amylin Pharmaceuticals: BYETTA package insert, 2008. Available online from http://pi.lilly.com/us/byetta-pi.pdf. Accessed 22 September 2010.
  27. U.S. Food and Drug Administration: Information for healthcare professionals: acute pancreatitis and sitagliptin (marketed as Januvia and Janumet), 2009. Available online from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed 22 September 2010.
  28. Noel RA, et al. Increased risk of acut pancreatitis and biliary disease observed in patients with tipy 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32(5):834-38.
  29. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
  30. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemia and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
  31. Nauck MA, Frid A, Hermansen K, et al.; for the LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009;32(1):84-90.
  32. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009;52:2046-55.
  33. Zinman B, Gerich J, Buse J, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-30.
  34. Bjerre Knudsen L, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-1486.
  35. Garber A. AACE Statement on Liraglutide (March 2010). Accessed June 24,2011.
  36. Jacobsen LV, et al. Pharmacokinetics of the long-acting human GLP-1 analog liraglutide in subjects with renal impairment. Diabetes 2007;56(Suppl 1):A137.
  37. Flint A, et al. Influence io hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analog liraglutide. Diabetes 2007;56(Suppl. 1):145.
  38. Дедов И.И., Шестакова М.В. и др. Алгоритмы специализированной медицинской помощи больным с сахарным диабетом (5-й выпуск) // Сахарный диабет. 2011. № 4. (Приложение). 72 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies